SynDevRx, Inc
- Biotech or pharma, therapeutic R&D
SynDevRx leads the innovative and emerging metabo-oncology space - the intersection of cancer and obesity. Our advanced lead drug evexomostat is in 2 Phase 2 studies for metastatic breast cancer, and we're opening a pilot study in neuroendocrine prostate cancer in 2025.
Evexomostat has single-agent anti-tumor activity, plus addresses the key underlying metabolic drivers of cancers sensitive to hormones.
Metabo-oncology market is estimated market >$40B
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}